-       Report 
   - August 2025
    -  191 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  189 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                -       Report 
   - December 2024
    -  125 Pages 
    Global
   
   From       €4179EUR$4,650USD£3,665GBP 
                  -       Report 
   - August 2025
    -  193 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                 -       Report 
   - March 2025
    -  200 Pages 
    Global
   
   From       €2238EUR$2,490USD£1,963GBP 
                -       Report 
   - November 2025
    -  189 Pages 
    Global
   
   From       €5258EUR$5,850USD£4,611GBP 
                -       Report 
   - September 2025
    -  250 Pages 
    Global
   
   From       €4036EUR$4,490USD£3,539GBP 
                  -       Report 
   - October 2025
    -  183 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Report 
   - August 2025
    -  184 Pages 
    Global
   
   From       €3186EUR$3,545USD£2,794GBP 
      €3540EUR$3,939USD£3,105GBP 
                  -       Clinical Trials 
   - April 2025
    -  280 Pages 
    Global
   
   From       €2157EUR$2,400USD£1,892GBP 
      €2696EUR$3,000USD£2,365GBP 
                  -       Clinical Trials 
   - April 2025
    -  240 Pages 
    Global
   
   From       €2157EUR$2,400USD£1,892GBP 
      €2696EUR$3,000USD£2,365GBP 
                  -       Report 
   - April 2025
    -  200 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - February 2025
    -  150 Pages 
    Global
   
   From       €2291EUR$2,549USD£2,009GBP 
      €2696EUR$2,999USD£2,364GBP 
                -       Report 
   - June 2025
    -  150 Pages 
    Global
   
   From       €2426EUR$2,699USD£2,128GBP 
                -       Report 
   - June 2025
    -  400 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - July 2025
    -  200 Pages 
    United States
   
   From       €2238EUR$2,490USD£1,963GBP 
                -       Report 
   - December 2022
    -  196 Pages 
    Global
   
   From       €4662EUR$5,368USD£3,950GBP 
                -       Report 
   - June 2025
    -  110 Pages 
    United Kingdom
   
   From       €4449EUR$4,950USD£3,902GBP 
                -       Report 
   - June 2023
    -  103 Pages 
    Global
   
   From       €5348EUR$5,950USD£4,690GBP 
             
         Galantamine is a drug used to treat mild to moderate Alzheimer's Disease. It is an acetylcholinesterase inhibitor, meaning it works by increasing the amount of the neurotransmitter acetylcholine in the brain. This helps to improve memory, thinking, and behavior in people with Alzheimer's. Galantamine is available in both oral and intravenous forms, and is often used in combination with other Alzheimer's medications. It is generally well-tolerated, with the most common side effects being nausea,    vomiting, and diarrhea.
Galantamine is one of several drugs used to treat Alzheimer's Disease, and is often prescribed alongside other medications such as donepezil and memantine. It is available in generic form, as well as under the brand names Razadyne and Reminyl.
Companies in the Galantamine market include Janssen Pharmaceuticals, Eisai Co., Ltd., and Shire Pharmaceuticals. Show Less   Read more